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in CR1 achieved sustained remissions using autoSCT. Of
those who relapse, nearly 50% proceed to alloSCT and 31%
are long-term disease-free survivors. Relapse-free survival
has likely decreased in the most recent era due to changes
in patient selection. AutoSCT remains a reasonable option
for int-risk patients with AML in CR1, with outcomes
rivaling those currently achieved with alternative donor
alloSCT.163
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Multiple Myeloma during High Dose Chemotherapy and
Autologous Stem Cell Transplant
Ahmad Hatem Mattour 1, Nalini Janakiraman 2,
Shatha Farhan 2, Edward Peres 2. 1Hematology-Oncology,
Henry Ford Health System, Detroit, MI; 2 Hematology/Oncology
and Bone Marrow Transplantation, Henry Ford Hospital,
Detroit, MI
Background: High dose chemotherapy (HDC) followed by
autologous stem cell transplant (ASCT) is considered the
standard of care for patients with multiple myeloma (MM).
With most patients receiving induction therapy that in-
cludes corticosteroids. The combined effect of prior ther-
apy for myeloma and ASCT related complications may
result in hypotension and require intensive medical
treatment. To date the incidence of adrenal insufﬁciency in
the setting of ASCT is unknown. The effects of this under-
lying disorder in regards to post transplant outcome
remain unknown as well. We set out to compare the out-
comes of patients with multiple myeloma who underwent
ASCT with adrenal insufﬁciency compared to those with
sufﬁcient adrenal function.
Methods: This was a prospective study in 13 consecutive
patients with MM admitted for HDC and ASCT at Henry Ford
Hospital between February 2014 through June 2014, with
the ﬁrst patient sample being obtained in on 2/14/2014 and
last sample recorded in 6/23/2014. Random cortisol levels
were obtained on the day of admission or day -2 (Figure 1),
prior to the start of HDC. All prior therapies included
corticosteroids and consisted of the following RVD, DCEP,
RD, VD, DT-PACE. Patients were classiﬁed into twoFigure 1groups those with cortisol levels > 5 and those patients
who had cortisol levels <5. Endpoints analyzed included
hypotension, septic shock, and duration of antibiotic
therapy.
Results: Of the 13 patients analyzed the median age was 60
years old (range 53-78), gender 8 male patients 5 female.
All patients underwent HDC with Melphalan and ASCT. Of
the 13 patients in which data was obtained 3/13 23% had
adrenal insufﬁciency prior to high dose Melphalan and
ASCT. With a median cortisol level of 3.2 in the patient
cohort who were found to be adrenal insufﬁcient. The
incidence of hypotension was 2/3 66% in the adrenal
insufﬁcient patients compared 1/10 10% in the cohort with
sufﬁcient adrenal function. Septic shock occurred in 2/3
66% of the adrenal insufﬁcient compared to 0/10 in the
adrenal sufﬁcient group. The median duration of antibiotic
therapy was 5 days in the adrenal insufﬁcient cohort
compared to 2 days in the patients with adequate adrenal
function.
Conclusion: In this small cohort of consecutive patients from
a single center, we found that there was a high incidence of
adrenal insufﬁciency 23% in patients undergoing ASCT. The
treatment regimens varied in the study group with all pa-
tients receiving corticosteroid therapy in their induction
regimen. Given the unexpectedly high incidence of adrenal
insufﬁciency a consideration should be given to check a
random cortisol level prior to the initiation of HDC. Supple-
mental therapy or treatment should be considered in this
high risk group to avoid unnecessary complications and
prolonged antibiotic use and supportive care in this patient
cohort.
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Stem Cell Infusion Adverse Reaction (SCIAR). Review of
Published Literature from Recent Years
Mehboob Merchant 1, Ann V. LeFever 1, Leo I. Gordon 1,2.
1Mathews Center for Cellular Therapy, Northwestern Memorial
Hospital, Chicago, IL; 2Northwestern University Medical
School, Division of Hem/Onc, Chicago, IL
Background: SCIAR are often seen during transplants, but
enough data are not available. In the past SCIAR were
attributed to adverse event (AE) from DMSO..
Table 1
Systems Symptoms
G-I Nausea vomiting abdominal pain cramping
Respiratory Cough dys/tachypnoea hypoxia SOB TRALI
Cardiac Hypo/hypertension brady/tachycardia arrhythmia chest
heaviness/pain MI cardiac arrest
Neuro Amnesia seizure stroke numbness uc
Other Fever chills ﬂushing headache hypothermia anxiety
vertigo allergy visual neuropathy back pain
Cause of SCIAR is either the graft (DMSO, cell content, volume, clumping) or
the patient (age, gender, disease).
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causative factors and associated symptoms to guard for AE
during infusion.
Method: Study of published literature as available on
PubMed website in the last 7 years.
Result: 11 articles by authors from diverse nations were
reviewed. Only 1 publication is from USA. Reports
are for autologous cryopreserved HPC-A (including few
allogeneic or marrow products). 3 studies reported
SCIAR after DMSO wash. Data size is from 51-952 in-
fusions. AE ranges from 0.6 to 67%. Various symptoms
are reported.
Discussion: Minor AE are attributed to DMSO, AE from
washed cells to granulocyte or TNC content of graft.
Cordoba R et al have reported 67% SCIAR despite DMSO
wash. 7 years ago, Donmez A et al (Turkey) suggested re-
striction of infusion to <100 E+9 TNC; and Wang JW et al
(China) advised fractionated infusions (vs. single infusion)
in pediatric patients. Khera N et al (USA) have compared 2
groups over 2 years reporting 0.6% SCIAR on infusion of
<1.63 E+9 TNC/Kg/day, fractionating infusions on different
days.
Conclusion: Despite multiple variables, transplant
centers can lower incidence of SCIAR by restricting graft
dose.Table 2
Article Infusions AE % Finding/Symptoms
Feb 07
Donmez A, Turkey
194
Allo 25
25
0
Non cardiac > cardiac
Apr 07
Wang JW, China
Ped 70 x G-I
Jun 07
Mueller LP, Germany
51 2 Cardiac ^DMSO
Jul 07
Calmels B, France
490 (washed) 14 x
Nov 07
Foïs E, France
952 (washed) 19 x
Dec 07
Cordoba R, Spain
144 (washed) 67 Allergic > G-I >
Respiratory
2007
Milone G, Italy
HPC-A 157
HPC-M 22
31
5
Cardiac ^vol/kg & inf time
Non cardiac ^age & non-MNC
Jul 08
Bojanic I, Croatia
215 57 1 symptom 21%
>1 36%
Jul 10
Curcioli AC, Brazil
114
Allo 47
Haplo 5
58 DMSO but not DMSO vol
Oct 10
Martìn-Henao GA, Spain
423 25 G-I
Respiratory
Seizure 0.7%
Feb 12
Khera N, USA
(Comparative)
2006-07: 288
2008-09: 479
4
0.6
Infusions increased 4 fold165
Severe Mucositis with Bendamustine Etoposide Ara-C and
Melphalan (Be-EAM) As Conditioning Regimen in Non-
Hodgkin Lymphoma (NHL) Patients Undergoing
Autologous Stem Cell Transplantation (AutoSCT)
Sunita Nathan 1, Antonio M. Jimenez 2, Alfonso D. Moreno 1,
John Maciejewski 3, Henry C. Fung 4. 1 Section of Bone
Marrow Transplant and Cell Therapy, Rush University Medical
Center, Chicago, IL; 2 Rush University Medical Center, Chicago,
IL; 3 Section of Bone Marrow Transplantation and Cell Therapy,
Rush University Medical Center, Chicago, IL; 4 Bone Marrow
Transplant Program, Temple University Hospital/Fox Chase
Cancer Center, Philadelphia, PA
Introduction: Bendamustine is effective for front-line or
salvage therapy in patients (pts) with NHL. Benda-EAM
conditioning has been used in heavily pre-treated relapsed/
refractory lymphoma pts undergoing autologous stem cell
transplantation (AutoSCT) and is noted to be a safe and
effective regimen. We report our experience with using Be-
EAM conditioning regimen for AutoSCT with special note on
the toxicity proﬁle.
Methods: Data from 22 consecutive patients (pts), under-
going AutoSCT using the Be-EAM [Bendamustine200mg/m2
daily D-7,-6, Etoposide 200mg/m2 daily D-5 to -2, Ara-C
200mg/m2 Q12 D-5 to -2 and Melphalan 140mg/m2 on D-1],
treated at our institution between 2011 and 2013, were
collected. Demographics, indication for AutoSCT, time to
engraftment (TE), side effect proﬁle, tolerability and out-
comes were analyzed. WHO oral mucositis score was used
for grading mucositis.
Results: 22 pts (average age 60.36 yrs, range: 39-72 yrs)
were identiﬁed and analyzed as a retrospective cohort
with a follow-up duration of 26.1 months (Range 9-43
mos). 15 (68%) pts were male and 7 (32%) pts fe-
male. 72.7% were Caucasian. 8 (36.4%) pts had 2AE Cause Suggestion/Conclusion
Vol infused
DMSO
TNC
 100 E+9 TNC
Single vol infusion Fractionated infusion
Neurotoxicity unrelated to DMSO vol DMSO safe in neurologic disease
TNC Improve apheresis quality
TNC
Clumps
AE ^TNC
Granulocyte
Clumping
 6.065 E+9 granulocytes
Age
Non-MNC
 5.0 E+8 non-MNC
Female gender
Multiple myeloma
Granulocyte
AE ^graft composition & disease
DMSO Good documentation required
AE ^granulocyte x
x  1.63 E+9 TNC/Kg/Day
Multiple infusions
